Melanoma in Black Patients: A Clinical Evidence Checklist
Prompt clinical evaluation remains the cornerstone of favorable skin cancer outcomes, yet significant disparities in tumor characteristics and survival persist across demographic groups. Public health initiatives frequently concentrate on sun-exposed surfaces, but medical data demonstrate distinct anatomic distributions and clinical features in individuals with darker skin tones. A 2024 JAMA Dermatology study on melanoma in Black patients analyzed patient-level and tumor-level records to clarify these presentation patterns. Below is an evidence-based clinical checklist exploring what the findings show.
Checklist Step: Thoroughly Inspect Acral Surfaces
Routine skin examinations in Black patients must place careful emphasis on acral skin, which includes the palms, soles of the feet, and nail beds. In the retrospective analysis, clinicians evaluated 40 primary cutaneous melanomas. A total of 30 (75%) of these 40 primary cutaneous melanomas were situated on acral sites.
Notably, only 10 of 30 (33%) of those acral lesions were histologically classified as acral lentiginous melanomas. This means that a tumor located on the foot or hand is not always categorized as the classic acral lentiginous subtype under a microscope, reinforcing the need for formal clinical biopsy. Essential areas to evaluate during regular skin checks include:
- The soles of the feet, heel margins, and the spaces between the toes.
- The palms of both hands and skin creases on the fingers.
- The nail beds of both fingers and toes for solitary pigmented bands or discoloration.
Checklist Step: Review Immune History and Prior Malignancies
The research identified meaningful differences when comparing tumors on nonacral skin with those on acral sites. Patients with nonacral cutaneous melanomas exhibited distinctive medical backgrounds:
- Patients presenting with nonacral cutaneous tumors were more likely to be immunocompromised (4 of 10 [40%] compared with 2 of 30 [7%] of those with acral lesions).
- A personal history of cancer was also significantly more frequent in individuals with nonacral melanomas (6 of 10 [60%] versus 5 of 30 [17%] among acral cases).
- All 3 patients in the cohort diagnosed with superficial spreading melanoma had a recorded history of both immunosuppression and prior cancer.
Understanding these underlying systemic influences is essential for healthcare providers assessing risk; readers can explore broader scientific findings regarding pigment and ultraviolet rays in our guide to UV exposure and melanoma in skin of color.
Checklist Step: Track Advanced Presentation and Tumor Genetics
Diagnostic delays frequently allow tumors to progress before formal identification occurs. Across the study cohort, 13 Black patients (27%) developed stage IV disease, of whom 12 died because of disease progression. No patients had more than 1 confirmed primary melanoma.
Individuals diagnosed with advanced acral melanoma, mucosal or ocular forms, or melanoma of unknown primary origin faced severe clinical hurdles. These advanced cases lacked actionable sequence variations, proved nonresponsive to immunotherapy, and had the poorest outcomes. In stark contrast, no patients with nonacral cutaneous melanomas in this cohort developed distant metastases or died of melanoma, showing how critical early anatomical differentiation is during initial assessment.
Checklist Step: Understand the Study Design and Scientific Limits
When reviewing medical literature, placing clinical data in proper context prevents overstating conclusions. The paper, titled Clinical Features and Outcomes of Black Patients With Melanoma, utilized a retrospective case series design.
The investigation gathered data from 2 tertiary care centers—University of Texas Southwestern Medical Center and Parkland Health—both affiliated with a single institution (UTSW in Dallas, Texas). Investigators reviewed records for self-reported Black patients diagnosed between January 2006 and October 2022. The entire series comprised 48 Black patients, with a median age at diagnosis of 62 years; 30 patients (63%) were female.
Because the investigation was a single-institution case series with a focused sample size, the results describe a specific clinical population and cannot be generalized across every clinical setting. The authors underscored that building multi-institutional registries will be necessary to deepen understanding and capture precise patient-level and tumor-level features across wider populations.
Checklist Step: Prioritize Dermatologic Care Over Unregulated Products
Because melanoma signs in deeply pigmented skin often develop in areas shielded from sunlight, relying strictly on traditional educational checklists like the ABCDE mole check may cause non-pigmented or subungual growths to be overlooked. Professional evaluation by a board-certified dermatologist remains the gold standard for investigating unusual or shifting skin spots.
Furthermore, individuals researching tanning practices should be aware that unapproved, unregulated compounds such as black-market melanotan I or melanotan II injections offer no cancer protection and carry significant health hazards. These products are unapproved by regulatory bodies and bypass vital quality safeguards. Always consult a physician or dermatologist for any suspicious skin growth rather than turning to unverified online products.
Sources
JAMA Dermatology: Clinical Features and Outcomes of Black Patients With Melanoma
Published October 31, 2026. Sources are linked in the text. See our Medical Disclaimer.